There is a growing body of literature suggesting that monoclonal antibody could be
efficacious in infants with RSV-bronchiolitis, well tolerated with no or clinically
insignificant adverse effects.
"The investigators hypothesize that a single dose of iv palivizumab 15 mg/kg in diagnosed
infants <3 months old with RSV bronchiolitis will result in fewer infants with readmissions
to infirmary/observation or hospital for relapse during 3 weeks of follow-up after
discharge".